Plamotamab

BIOLOGICAL2 trials

Sponsors

Xencor, Inc.

Conditions

Diffuse Large-cell B-cell LymphomaRheumatoid Arthritis

Phase 1

A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis

RecruitingNCT07230353

Xencor, Inc.Rheumatoid Arthritis

Start: 2025-10-21End: 2028-06-01Target: 68Updated: 2026-08-03

Phase 2

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

TerminatedNCT05328102

Xencor, Inc.Diffuse Large-cell B-cell Lymphoma

Start: 2022-04-15End: 2023-02-21Updated: 2024-04-30